Galina P. Tereshchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Galina P. Tereshchenko has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Aida Guseykhanovna Gadzhigoroeva
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology; Peoples’ Friendship University of Russia named after Patrice Lumumba
14 shared publications - Olga V. Zhukova
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology; RUDN University
14 shared publications - Nikolay Nikolaevich Potekaev
Pirogov Russian National Research Medical University; Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology
12 shared publications - Aleksey L. Savastenko
Peoples’ Friendship University of Russia named after Patrice Lumumba
4 shared publications - Maria N. Ostretsova
RUDN University
4 shared publications - Alaa A.M. Nemer
Peoples’ Friendship University of Russia
3 shared publications
Latest Publications
- 28 August 2026
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 25 (4)
Clinical and Immunological Phenotypes of Alopecia Areata in Children with Concomitant Atopic Dermatitis: Results of a Cluster Analysis
Background. Alopecia areata (AA) and atopic dermatitis (AD) are chronic immune-mediated diseases that frequently coexist in children. Despite established epidemiological links, the internal structure of this comorbidity, including how objective disease severity and polyatopy correlate, remains poorly characterized. Aim. To identify and characterize clinical-immunological phenotypes of AA in children with concomitant AD using cluster analysis. Methods. A single-center, cross-sectional study included 68 children aged 5—16 years with AA and AD. Assessments included disease severity (SALT, SCORAD), age of AA onset, serum total IgE, quality of life (CDLQI), and atopic comorbidity (Atopy Index: 0=AD only, 1=+1 atopic condition, 2=+≥2 conditions). Spearman’s correlation and k-means clustering (variables: SALT, SCORAD, IgE, age of AA onset) were used. Results. Correlation analysis revealed a moderate positive association between AA and AD severity (ρ=+0.512, p<0.001). Earlier AA onset correlated significantly with more severe hair loss (ρ=–0.418, p=0.001). Cluster analysis identified three distinct phenotypes: (1) «Early-Onset, Severe AA» (n=22): Early onset (3.0 years), universal hair loss (SALT 100.0%), high CDLQI (11.0); (2) «Late-Onset, Mild Disease» (n=25): Later onset (8.0 years), mild AA (SALT 18.8%) and AD (SCORAD 22.6), lowest IgE (87.6 IU/mL); (3) «Severe Atopic» (n=21): Extreme atopy with highest IgE (847.0 IU/mL), severe AD (SCORAD 52.7) and AA (SALT 77.5%). A higher Atopy Index was associated with increased AD severity (p=0.003) and IgE levels (p=0.015). Conclusion. This study reveals significant heterogeneity in pediatric AA with AD, delineating distinct phenotypic profiles. The findings suggest at least two pathways to severe alopecia: one driven by very early disease onset and another by a severe, systemic Th2 atopic burden. Stratification by age of onset, disease severity, and atopic load facilitates personalized management and identifies children at the highest risk for severe disease and quality of life impairment.
- 28 August 2026
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 25 (4)
Clinical and Immunological Phenotypes of Alopecia Areata in Children with Concomitant Atopic Dermatitis: Results of a Cluster Analysis
Background. Alopecia areata (AA) and atopic dermatitis (AD) are chronic immune-mediated diseases that frequently coexist in children. Despite established epidemiological links, the internal structure of this comorbidity, including how objective disease severity and polyatopy correlate, remains poorly characterized. Aim. To identify and characterize clinical-immunological phenotypes of AA in children with concomitant AD using cluster analysis. Methods. A single-center, cross-sectional study included 68 children aged 5—16 years with AA and AD. Assessments included disease severity (SALT, SCORAD), age of AA onset, serum total IgE, quality of life (CDLQI), and atopic comorbidity (Atopy Index: 0=AD only, 1=+1 atopic condition, 2=+≥2 conditions). Spearman’s correlation and k-means clustering (variables: SALT, SCORAD, IgE, age of AA onset) were used. Results. Correlation analysis revealed a moderate positive association between AA and AD severity (ρ=+0.512, p<0.001). Earlier AA onset correlated significantly with more severe hair loss (ρ=–0.418, p=0.001). Cluster analysis identified three distinct phenotypes: (1) «Early-Onset, Severe AA» (n=22): Early onset (3.0 years), universal hair loss (SALT 100.0%), high CDLQI (11.0); (2) «Late-Onset, Mild Disease» (n=25): Later onset (8.0 years), mild AA (SALT 18.8%) and AD (SCORAD 22.6), lowest IgE (87.6 IU/mL); (3) «Severe Atopic» (n=21): Extreme atopy with highest IgE (847.0 IU/mL), severe AD (SCORAD 52.7) and AA (SALT 77.5%). A higher Atopy Index was associated with increased AD severity (p=0.003) and IgE levels (p=0.015). Conclusion. This study reveals significant heterogeneity in pediatric AA with AD, delineating distinct phenotypic profiles. The findings suggest at least two pathways to severe alopecia: one driven by very early disease onset and another by a severe, systemic Th2 atopic burden. Stratification by age of onset, disease severity, and atopic load facilitates personalized management and identifies children at the highest risk for severe disease and quality of life impairment.
- 30 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 25 (2) , 169-177
Alopecia areata morbidity structure considering the association with atopic dermatitis in the population of Moscow in comparison with data from the federal register
Background. Alopecia areata (AA) is an autoimmune disease in which association with atopic dermatitis (AD) is one of the prognostically adverse factors. The relevance of studying the structure of AA morbidity taking into account atopic comorbidity is caused by the lack of modern epidemiological data and age differences in clinical manifestations. Objective. To study the structure of AA morbidity in the population of Moscow and the federal register with emphasis on association with AD. Material and methods. A multicenter retrospective cohort study was carried out on the basis of data from the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology (MSPCDC) and the register of adult patients with AA for 2020—2024. The analysis included stratification according to ICD-10 (L63.0—L63.8), age groups (children aged 0—17 years and adults aged 18 years and older), assessment of association with AD (L20.8), calculation of extensive and intensive indicators (per 100 000 population). Methods of descriptive and analytical statistics were used: logistic regression, χ² and Mann—Whitney U tests, Bonferroni correction. Results. Prevalence of local forms (L63.8—84.9%) with a steady increase in their proportion (+3.2 p.p., p<0.001) especially among children (+8.6 p.p.) was revealed. Severe forms (L63.0—L63.2) amounted to 15.1%, more frequently occurring in children (15.2% versus 12.6%, p<0.05), especially ophiasis (1.7 times more frequent, p=0.013). Association with AD was noted in 2.7% of patients with maximum increase in children (+2.2 p.p., p=0.013). For comorbidity with AD, alopecia totalis (18.2% versus 8.1% in the overall group, OR 2.47, p<0.001) and universalis (7.4% versus 3.0%, OR 2.41, p=0.003) predominated. In the register (n=403), AD was diagnosed in 15.9% of patients predominantly with alopecia universalis (27.9%, OR 4.2, p<0.001). Conclusion. The significant association of severe forms of AA with AD emphasizes the importance of considering the atopic background in assessing the clinical course of alopecia.
- 30 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 25 (2) , 169-177
Alopecia areata morbidity structure considering the association with atopic dermatitis in the population of Moscow in comparison with data from the federal register
Background. Alopecia areata (AA) is an autoimmune disease in which association with atopic dermatitis (AD) is one of the prognostically adverse factors. The relevance of studying the structure of AA morbidity taking into account atopic comorbidity is caused by the lack of modern epidemiological data and age differences in clinical manifestations. Objective. To study the structure of AA morbidity in the population of Moscow and the federal register with emphasis on association with AD. Material and methods. A multicenter retrospective cohort study was carried out on the basis of data from the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology (MSPCDC) and the register of adult patients with AA for 2020—2024. The analysis included stratification according to ICD-10 (L63.0—L63.8), age groups (children aged 0—17 years and adults aged 18 years and older), assessment of association with AD (L20.8), calculation of extensive and intensive indicators (per 100 000 population). Methods of descriptive and analytical statistics were used: logistic regression, χ² and Mann—Whitney U tests, Bonferroni correction. Results. Prevalence of local forms (L63.8—84.9%) with a steady increase in their proportion (+3.2 p.p., p<0.001) especially among children (+8.6 p.p.) was revealed. Severe forms (L63.0—L63.2) amounted to 15.1%, more frequently occurring in children (15.2% versus 12.6%, p<0.05), especially ophiasis (1.7 times more frequent, p=0.013). Association with AD was noted in 2.7% of patients with maximum increase in children (+2.2 p.p., p=0.013). For comorbidity with AD, alopecia totalis (18.2% versus 8.1% in the overall group, OR 2.47, p<0.001) and universalis (7.4% versus 3.0%, OR 2.41, p=0.003) predominated. In the register (n=403), AD was diagnosed in 15.9% of patients predominantly with alopecia universalis (27.9%, OR 4.2, p<0.001). Conclusion. The significant association of severe forms of AA with AD emphasizes the importance of considering the atopic background in assessing the clinical course of alopecia.
- 16 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 14-23
Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Introduction . Tofacitinib and baricitinib are key systemic therapies for alopecia areata. However, direct comparative data on their efficacy and predictors of treatment response in real-world practice are limited. Aim . To compare the efficacy of tofacitinib and baricitinib in alopecia areata and identify predictors of treatment response. Materials and methods . A 52-week prospective comparative non-randomized cohort study included 45 patients with alopecia areata (SALT >25%). Patients were divided into two groups: tofacitinib (n = 18,10 mg daily) and baricitinib (n = 27,4 mg daily). Efficacy was assessed using SALT score dynamics, SALT30 (≥30% reduction), and SALT ≤20% (clinically significant outcome). Multiple regression models and Cox regression were used to identify predictors. Results . Groups differed in age and sex (p < 0.05). At week 52, the median hair regrowth was 81.4% for tofacitinib and 100.0% for baricitinib (p = 0.280). Achievement of SALT30 and SALT ≤20% was comparable (p > 0.05). Multivariate analysis identified baseline disease severity (SALT) as the only independent predictor of poorer response (β = -2.6% per 10% SALT, p = 0.047; OR for SALT ≤20% = 0.78, p = 0.038). Drug choice was not associated with efficacy. However, the proportion of early responders (SALT30 by week 12) was significantly higher with baricitinib (51.9% vs. 22.2%, p = 0.041). No serious adverse events occurred. Conclusions . Tofacitinib and baricitinib demonstrate comparable efficacy and a favorable safety profile in alopecia areata. Baricitinib is associated with a higher rate of early responders. The key predictor of response is the baseline extent of hair loss, which must be considered when planning therapy and evaluating outcomes.
- 16 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 14-23
Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Introduction . Tofacitinib and baricitinib are key systemic therapies for alopecia areata. However, direct comparative data on their efficacy and predictors of treatment response in real-world practice are limited. Aim . To compare the efficacy of tofacitinib and baricitinib in alopecia areata and identify predictors of treatment response. Materials and methods . A 52-week prospective comparative non-randomized cohort study included 45 patients with alopecia areata (SALT >25%). Patients were divided into two groups: tofacitinib (n = 18,10 mg daily) and baricitinib (n = 27,4 mg daily). Efficacy was assessed using SALT score dynamics, SALT30 (≥30% reduction), and SALT ≤20% (clinically significant outcome). Multiple regression models and Cox regression were used to identify predictors. Results . Groups differed in age and sex (p < 0.05). At week 52, the median hair regrowth was 81.4% for tofacitinib and 100.0% for baricitinib (p = 0.280). Achievement of SALT30 and SALT ≤20% was comparable (p > 0.05). Multivariate analysis identified baseline disease severity (SALT) as the only independent predictor of poorer response (β = -2.6% per 10% SALT, p = 0.047; OR for SALT ≤20% = 0.78, p = 0.038). Drug choice was not associated with efficacy. However, the proportion of early responders (SALT30 by week 12) was significantly higher with baricitinib (51.9% vs. 22.2%, p = 0.041). No serious adverse events occurred. Conclusions . Tofacitinib and baricitinib demonstrate comparable efficacy and a favorable safety profile in alopecia areata. Baricitinib is associated with a higher rate of early responders. The key predictor of response is the baseline extent of hair loss, which must be considered when planning therapy and evaluating outcomes.
- Open Access
- 30 September 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 212-223
Epidemiology of alopecia areata and its association with atopic dermatitis: A comparative analysis of data from the Moscow Center of Dermatovenereology and Cosmetology and the Federal Registry
Introduction. One of the frequent comorbid conditions in alopecia areata is atopic dermatitis. Existing epidemiological data on alopecia areata and its association with atopic dermatitis remain contradictory and insufficiently studied, which underscores the relevance of this research.Aim. To study the epidemiological characteristics of alopecia areata in Moscow and its association with atopic dermatitis based on population and registry data.Materials and methods. A multicenter retrospective cohort study was conducted by analyzing medical records of patients diagnosed with alopecia areata and atopic dermatitis monitored at the Moscow Center for Dermatovenereology and Cosmetology from 2020 to 2024. Federal statistics (Form No. 12), outpatient records (No. 025/u-04), and a specialized alopecia areata registry were used. Rates per 100 000 population were calculated.Results. Significant differences in alopecia areata epidemiology were found (p < 0.001): prevalence in children (36.8/100 000) was 2.7 times higher than in adults (13.7/100 000), incidence – 22.2 vs. 7.9/100 000/year. Overall morbidity increased by +83.3%, prevalence by +62.6% (p < 0.001). The association between alopecia areata and atopic dermatitis was significant (p < 0.001): overall frequency 2.66% (95% CI: 2.37–2.95), higher in children (4.09%; OR = 8.3, 95% CI: 7.1–9.7) than adults (1.85%; OR = 14.1, 95% CI: 11.9–16.7). The highest increase occurred in 2021. In the adult alopecia areata registry, atopic dermatitis was present in 15.9% (64/403).Conclusions. The significant age-dependent association between alopecia areata and atopic dermatitis confirms atopic dermatitis as an established risk factor. Registry data provide more accurate information on comorbidities. The results justify screening for atopy in alopecia areata patients and the need for a multidisciplinary management approach.
- 30 September 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 212-223
Open AccessEpidemiology of alopecia areata and its association with atopic dermatitis: A comparative analysis of data from the Moscow Center of Dermatovenereology and Cosmetology and the Federal Registry
Introduction. One of the frequent comorbid conditions in alopecia areata is atopic dermatitis. Existing epidemiological data on alopecia areata and its association with atopic dermatitis remain contradictory and insufficiently studied, which underscores the relevance of this research.Aim. To study the epidemiological characteristics of alopecia areata in Moscow and its association with atopic dermatitis based on population and registry data.Materials and methods. A multicenter retrospective cohort study was conducted by analyzing medical records of patients diagnosed with alopecia areata and atopic dermatitis monitored at the Moscow Center for Dermatovenereology and Cosmetology from 2020 to 2024. Federal statistics (Form No. 12), outpatient records (No. 025/u-04), and a specialized alopecia areata registry were used. Rates per 100 000 population were calculated.Results. Significant differences in alopecia areata epidemiology were found (p < 0.001): prevalence in children (36.8/100 000) was 2.7 times higher than in adults (13.7/100 000), incidence – 22.2 vs. 7.9/100 000/year. Overall morbidity increased by +83.3%, prevalence by +62.6% (p < 0.001). The association between alopecia areata and atopic dermatitis was significant (p < 0.001): overall frequency 2.66% (95% CI: 2.37–2.95), higher in children (4.09%; OR = 8.3, 95% CI: 7.1–9.7) than adults (1.85%; OR = 14.1, 95% CI: 11.9–16.7). The highest increase occurred in 2021. In the adult alopecia areata registry, atopic dermatitis was present in 15.9% (64/403).Conclusions. The significant age-dependent association between alopecia areata and atopic dermatitis confirms atopic dermatitis as an established risk factor. Registry data provide more accurate information on comorbidities. The results justify screening for atopy in alopecia areata patients and the need for a multidisciplinary management approach.
- Open Access
- 29 August 2025
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 32 (4) , 82-95
Comparative evaluation of cytokine profiles in pediatric alopecia areata patients considering concomitant atopic diseases: An observational cohort cross-sectional study
Background. Alopecia areata is an autoimmune disease affecting hair follicles that is frequently associated with atopic diseases. Studies on cytokine profiles in the context of atopic comorbidities help to identify the key immune mechanisms and specific immunophenotypes. The present study aims to identify immune differences in alopecia areata depending on the atopic status.Objective. To assess the serum levels of the main proinflammatory and regulatory cytokines in patients with alopecia areata, taking the presence of atopic diseases and the severity of the process into account.Methods. An observational cohort cross-sectional study was conducted at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow City Health Department. The study included 44 alopecia areata patients aged 5–17 years, who were divided into two groups: 1) patients without atopy (n = 17); 2) patients with concomitant atopic diseases (n = 27). The severity of alopecia areata was graded using the Severity of Alopecia Tool (SALT). Cytokine concentration was studied via a multiplex assay (Luminex 200, ProcartaPlex Human Cytokine&Chemokine Panel 1A, 34plex). Of the 34 target parameters, granulocyte-macrophage colony-stimulating factor, interleukin-1β, and interleukin-15 were excluded from analysis due to the lack of detection in ≥20 participants. The remaining 31 parameters were compared between the groups and with the comparable healthy control group (n = 30). The correlation between the serum cytokine levels and alopecia severity was analyzed. The obtained data were statistically processed using Statistica 10.0 (StatSoft, USA) and Microsoft Excel 2016 (Microsoft Corporation, USA). The statistical significance level is α = 0.05. In order to estimate the correlation coefficient (r) and its statistical significance (p), Spearman’s coefficient was used. SCImagoGraphica software (SCImago LAB, Spain) was used for the graphic representation of the obtained results.Results. Differences between Groups 1–2 and the control group were found for 18 cytokines. Group 2 patients (with atopy) exhibited differences from the control group (p < 0.005) in the distribution of levels of all Type 2 cytokines, Type 1 cytokines (interleukin-2, interleukin-12, and tumor necrosis factor alpha and beta), and T helper 17 cytokines (interleukins 21, 22, 23, and 27), except for interleukin-17A. In Group 1 (without atopy), interleukin-4, interleukin-9, and eotaxin levels did not differ from those in the control group, while the level of interleukin-17A was elevated (p = 0.007). A direct comparison of the distribution of cytokine levels showed no statistically significant differences between Groups 1 and 2 in any of the parameters. The correlation between cytokine levels in alopecia areata patients and the disease severity was analyzed in all patients without dividing them according to their atopic status due to the limited sample size in the subgroups. The levels of interleukins 1 alpha, 10, 21, 22, 23, 27 and tumor necrosis factor beta were positively correlated with alopecia severity, especially interleukin-23 (r = 0.372, p = 0.008); a negative correlation with SALT scores was observed for interleukin-2 (r = −0.457, p = 0.011) and interleukin-4 (r = −0.489, p = 0.006).Conclusion. The obtained results confirm the complex and systemic nature of immune abnormalities in alopecia areata. T helper 2 cytokines are clearly involved in the pathophysiologic process, with comorbid atopic diseases enhancing the T helper 2 response, potentially modulating interleukin-17A expression. The severe course of alopecia is associated with the activation of T helper 17 mediators (except for interleukin-17A) and a decrease in the levels of interleukins 2 and 4. The obtained data justify the appropriateness of personalized therapy that takes the atopic status and cytokine profile into account.
- 29 August 2025
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 32 (4) , 82-95
Open AccessComparative evaluation of cytokine profiles in pediatric alopecia areata patients considering concomitant atopic diseases: An observational cohort cross-sectional study
Background. Alopecia areata is an autoimmune disease affecting hair follicles that is frequently associated with atopic diseases. Studies on cytokine profiles in the context of atopic comorbidities help to identify the key immune mechanisms and specific immunophenotypes. The present study aims to identify immune differences in alopecia areata depending on the atopic status.Objective. To assess the serum levels of the main proinflammatory and regulatory cytokines in patients with alopecia areata, taking the presence of atopic diseases and the severity of the process into account.Methods. An observational cohort cross-sectional study was conducted at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow City Health Department. The study included 44 alopecia areata patients aged 5–17 years, who were divided into two groups: 1) patients without atopy (n = 17); 2) patients with concomitant atopic diseases (n = 27). The severity of alopecia areata was graded using the Severity of Alopecia Tool (SALT). Cytokine concentration was studied via a multiplex assay (Luminex 200, ProcartaPlex Human Cytokine&Chemokine Panel 1A, 34plex). Of the 34 target parameters, granulocyte-macrophage colony-stimulating factor, interleukin-1β, and interleukin-15 were excluded from analysis due to the lack of detection in ≥20 participants. The remaining 31 parameters were compared between the groups and with the comparable healthy control group (n = 30). The correlation between the serum cytokine levels and alopecia severity was analyzed. The obtained data were statistically processed using Statistica 10.0 (StatSoft, USA) and Microsoft Excel 2016 (Microsoft Corporation, USA). The statistical significance level is α = 0.05. In order to estimate the correlation coefficient (r) and its statistical significance (p), Spearman’s coefficient was used. SCImagoGraphica software (SCImago LAB, Spain) was used for the graphic representation of the obtained results.Results. Differences between Groups 1–2 and the control group were found for 18 cytokines. Group 2 patients (with atopy) exhibited differences from the control group (p < 0.005) in the distribution of levels of all Type 2 cytokines, Type 1 cytokines (interleukin-2, interleukin-12, and tumor necrosis factor alpha and beta), and T helper 17 cytokines (interleukins 21, 22, 23, and 27), except for interleukin-17A. In Group 1 (without atopy), interleukin-4, interleukin-9, and eotaxin levels did not differ from those in the control group, while the level of interleukin-17A was elevated (p = 0.007). A direct comparison of the distribution of cytokine levels showed no statistically significant differences between Groups 1 and 2 in any of the parameters. The correlation between cytokine levels in alopecia areata patients and the disease severity was analyzed in all patients without dividing them according to their atopic status due to the limited sample size in the subgroups. The levels of interleukins 1 alpha, 10, 21, 22, 23, 27 and tumor necrosis factor beta were positively correlated with alopecia severity, especially interleukin-23 (r = 0.372, p = 0.008); a negative correlation with SALT scores was observed for interleukin-2 (r = −0.457, p = 0.011) and interleukin-4 (r = −0.489, p = 0.006).Conclusion. The obtained results confirm the complex and systemic nature of immune abnormalities in alopecia areata. T helper 2 cytokines are clearly involved in the pathophysiologic process, with comorbid atopic diseases enhancing the T helper 2 response, potentially modulating interleukin-17A expression. The severe course of alopecia is associated with the activation of T helper 17 mediators (except for interleukin-17A) and a decrease in the levels of interleukins 2 and 4. The obtained data justify the appropriateness of personalized therapy that takes the atopic status and cytokine profile into account.
- 1 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (3)
A clinical case of familial alopecia areata in combination with immune pathology
Alopecia areata (AA) is a chronic inflammatory disease that causes partial or complete hair loss and is based on autoimmune processes. Current studies are actively investigating the use of JAK inhibitors for AA treatment, but data on the safety and efficacy of these drugs in patients with congenital immunodeficiency are practically non-existent. A unique clinical case of familial form of severe AA in two sisters with congenital immune disorders, that caused certain difficulties in treatment, is presented. The older sister, 24 years old, has been diagnosed with primary immunodeficiency — selective IgA deficiency combined with IgG2 deficiency, and the younger sister, 18 years old, is under observation with suspicion of immunodeficiency with a predominant defect of antibodies. Both patients receive targeted therapy with tofacitinib, in presence of which a partial hair regeneration, more pronounced in the younger sister, has been noted. This clinical case emphasizes the need for multidisciplinary interaction of dermatologists, immunologists and geneticists in treating patients with AA and congenital immune disorders. Special attention should be paid to clinical and laboratory monitoring to minimize the risk of infections associated with therapy using JAK inhibitors. Our observation contributes to the understanding of genetic and immune mechanisms of AA and confirms the possibility of JAK inhibitors application in patients with autoimmune diseases affected by immunodeficiency. These data may serve as an addition to the development of new recommendations and treatment algorithms in such cases, and still the final efficacy and safety of such therapy require further study.
- 1 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (3)
A clinical case of familial alopecia areata in combination with immune pathology
Alopecia areata (AA) is a chronic inflammatory disease that causes partial or complete hair loss and is based on autoimmune processes. Current studies are actively investigating the use of JAK inhibitors for AA treatment, but data on the safety and efficacy of these drugs in patients with congenital immunodeficiency are practically non-existent. A unique clinical case of familial form of severe AA in two sisters with congenital immune disorders, that caused certain difficulties in treatment, is presented. The older sister, 24 years old, has been diagnosed with primary immunodeficiency — selective IgA deficiency combined with IgG2 deficiency, and the younger sister, 18 years old, is under observation with suspicion of immunodeficiency with a predominant defect of antibodies. Both patients receive targeted therapy with tofacitinib, in presence of which a partial hair regeneration, more pronounced in the younger sister, has been noted. This clinical case emphasizes the need for multidisciplinary interaction of dermatologists, immunologists and geneticists in treating patients with AA and congenital immune disorders. Special attention should be paid to clinical and laboratory monitoring to minimize the risk of infections associated with therapy using JAK inhibitors. Our observation contributes to the understanding of genetic and immune mechanisms of AA and confirms the possibility of JAK inhibitors application in patients with autoimmune diseases affected by immunodeficiency. These data may serve as an addition to the development of new recommendations and treatment algorithms in such cases, and still the final efficacy and safety of such therapy require further study.
- Open Access
- 13 May 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (3) , 277-286
Evaluation of antihistamine efficacy in combined therapy for alopecia areata
BACKGROUND: In treating alopecia areata, antihistamines such as fexofenadine and ebastine are considered adjuvant therapy, primarily in patients with concomitant allergic diseases. The insufficient understanding of their mechanisms of action and limited evidence of their efficacy in alopecia areata highlight the need for further research. AIM: To evaluate the efficacy of ebastine and fexofenadine combined with local therapy for the treatment of alopecia areata. MATERIALS AND METHODS: A 12-week prospective comparative cohort study included 91 patients with alopecia areata aged ≥12 years, some with atopic conditions. Participants were randomized into two groups: the main group (n = 43) received standard therapy for alopecia areata (intradermal injection of betamethasone suspension, 0.2 mL/cm2, not exceeding 1 ml, once) combined with oral ebastine 20 mg or fexofenadine 120 mg daily for 28 days; the comparison group received betamethasone alone. Antihistamines in the main group were prescribed for allergy management. Both groups were assessed for clinical and anamnestic data, baseline and post-treatment alopecia severity via SALT scores (%), and hair regrowth rates. RESULTS: The groups were matched in age, gender and current episode duration characterized by the active stage of alopecia areata. Baseline SALT indicated mild severity (median 22.4 %, interquartile range 13.45 in the main group; and median 19.3 %, interquartile range 15.53 % in the comparison group; p 0.05). All patients in the main group and 60.4 % of the comparison group had atopic comorbidities. At 12 weeks, the main group showed a reduction in SALT scores to a median value of 5.4 % (interquartile range 9.35 %), significantly lower than the comparison group (12.65 %, interquartile range 18.65 %; p = 0.002). Hair regrowth (%) was higher in the main group (72.04 %, interquartile range 35.73 % vs. 40.97 %, interquartile range 93.32 %; p = 0.01). Increased hair loss or negative regrowth occurred in 4.65 % of the main group vs. 31.25 % of the comparison group. CONCLUSION: The combination of fexofenadine or ebastine with local therapy significantly reduces alopecia areata severity and promotes hair regrowth compared to only topical treatment. These findings suggest a potential role of antihistamines in stabilizing the pathological process in hair follicles, enhancing treatment efficacy. Further investigation into histamine receptors’ role in alopecia areata pathogenesis is warranted.
- 13 May 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (3) , 277-286
Open AccessEvaluation of antihistamine efficacy in combined therapy for alopecia areata
BACKGROUND: In treating alopecia areata, antihistamines such as fexofenadine and ebastine are considered adjuvant therapy, primarily in patients with concomitant allergic diseases. The insufficient understanding of their mechanisms of action and limited evidence of their efficacy in alopecia areata highlight the need for further research. AIM: To evaluate the efficacy of ebastine and fexofenadine combined with local therapy for the treatment of alopecia areata. MATERIALS AND METHODS: A 12-week prospective comparative cohort study included 91 patients with alopecia areata aged ≥12 years, some with atopic conditions. Participants were randomized into two groups: the main group (n = 43) received standard therapy for alopecia areata (intradermal injection of betamethasone suspension, 0.2 mL/cm2, not exceeding 1 ml, once) combined with oral ebastine 20 mg or fexofenadine 120 mg daily for 28 days; the comparison group received betamethasone alone. Antihistamines in the main group were prescribed for allergy management. Both groups were assessed for clinical and anamnestic data, baseline and post-treatment alopecia severity via SALT scores (%), and hair regrowth rates. RESULTS: The groups were matched in age, gender and current episode duration characterized by the active stage of alopecia areata. Baseline SALT indicated mild severity (median 22.4 %, interquartile range 13.45 in the main group; and median 19.3 %, interquartile range 15.53 % in the comparison group; p 0.05). All patients in the main group and 60.4 % of the comparison group had atopic comorbidities. At 12 weeks, the main group showed a reduction in SALT scores to a median value of 5.4 % (interquartile range 9.35 %), significantly lower than the comparison group (12.65 %, interquartile range 18.65 %; p = 0.002). Hair regrowth (%) was higher in the main group (72.04 %, interquartile range 35.73 % vs. 40.97 %, interquartile range 93.32 %; p = 0.01). Increased hair loss or negative regrowth occurred in 4.65 % of the main group vs. 31.25 % of the comparison group. CONCLUSION: The combination of fexofenadine or ebastine with local therapy significantly reduces alopecia areata severity and promotes hair regrowth compared to only topical treatment. These findings suggest a potential role of antihistamines in stabilizing the pathological process in hair follicles, enhancing treatment efficacy. Further investigation into histamine receptors’ role in alopecia areata pathogenesis is warranted.
- Open Access
- 31 March 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 143-152
Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Introduction. Alopecia areata (AA) associated with atopic diseases (AD) is characterized by specific clinical, epidemiological, and immunological features, allowing the identification of an “atopic type” of AA. Currently, certain treatment methods may be effective for both AA and AD.Aim. To analyze current treatment options for “atopic” AA based on literature and clinical experience.Materials and methods. Review of publications concerning the connection between AA and atopy and treatment methods; assessment of clinical and laboratory data and treatment outcomes for patients with AA and AD.Results. Seventy-eight publications were analyzed, and two clinical cases were described. In the first case, a patient receiving dupilumab showed positive effects on universal AA, atopic dermatitis (AtD), and bronchial asthma. The second patient with AtD and subtotal AA achieved partial remission through combined therapy, including UVB 311 nm and antihistamines. Specific treatment options for comorbid AA and AD were identified. Notably, phototherapy used for AtD may aid in hair restoration; antihistamines used for AD symptoms are potentially effective for AA, particularly during active stage. For systemic therapy needs in AA and AtD, oral JAK inhibitors – baricitinib, upadacitinib, and abrocitinib – should be considered. Dupilumab may be the treatment of choice for AA with severe AtD and respiratory allergies, including in younger pediatric patients.Conclusions. The treatment strategy for patients with concomitant AA and AD should focus on reducing pharmacological burden and improving quality of life. Modern therapeutic approaches provide options for addressing shared pathological mechanisms while considering diseases severity and patient age.
- 31 March 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 143-152
Open AccessCurrent options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Introduction. Alopecia areata (AA) associated with atopic diseases (AD) is characterized by specific clinical, epidemiological, and immunological features, allowing the identification of an “atopic type” of AA. Currently, certain treatment methods may be effective for both AA and AD.Aim. To analyze current treatment options for “atopic” AA based on literature and clinical experience.Materials and methods. Review of publications concerning the connection between AA and atopy and treatment methods; assessment of clinical and laboratory data and treatment outcomes for patients with AA and AD.Results. Seventy-eight publications were analyzed, and two clinical cases were described. In the first case, a patient receiving dupilumab showed positive effects on universal AA, atopic dermatitis (AtD), and bronchial asthma. The second patient with AtD and subtotal AA achieved partial remission through combined therapy, including UVB 311 nm and antihistamines. Specific treatment options for comorbid AA and AD were identified. Notably, phototherapy used for AtD may aid in hair restoration; antihistamines used for AD symptoms are potentially effective for AA, particularly during active stage. For systemic therapy needs in AA and AtD, oral JAK inhibitors – baricitinib, upadacitinib, and abrocitinib – should be considered. Dupilumab may be the treatment of choice for AA with severe AtD and respiratory allergies, including in younger pediatric patients.Conclusions. The treatment strategy for patients with concomitant AA and AD should focus on reducing pharmacological burden and improving quality of life. Modern therapeutic approaches provide options for addressing shared pathological mechanisms while considering diseases severity and patient age.
- Open Access
- 15 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 124-132
Papulosquamous scalp dermatoses: key aspects of differential diagnosis and treatment
Psoriasis and seborrheic dermatitis are common papulosquamous dermatoses. When localized only on the scalp, they often have very similar clinical manifestations and require a comprehensive differential diagnostic approach. The article presents the main comparative clinical and diagnostic characteristics of psoriasis and seborrheic dermatitis of the scalp, including trichoscopy features and pathomorphological markers. Topical therapy with glucocorticosteroids, keratolytics and agents with antifungal activity is of key importance in the treatment of papulosquamous diseases. Modern topical drugs with a fixed combination of active ingredients provide an effect on several pathogenetic mechanisms at once, are stable, compatible, and convenient for use by patients. One of the main drugs for the treatment of psoriasis and seborrheic dermatitis is a solution of betamethasone dipropionate and salicylic acid (trade name – Akriderm SK), which in terms of anti-inflammatory activity is comparable to the highest strength topical corticosteroids, while providing a faster response to therapy and effectively relieving symptoms of itching and peeling. This is confirmed by the authors’ own clinical experience and demonstrated in the clinical cases described in the article.
- 15 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 124-132
Open AccessPapulosquamous scalp dermatoses: key aspects of differential diagnosis and treatment
Psoriasis and seborrheic dermatitis are common papulosquamous dermatoses. When localized only on the scalp, they often have very similar clinical manifestations and require a comprehensive differential diagnostic approach. The article presents the main comparative clinical and diagnostic characteristics of psoriasis and seborrheic dermatitis of the scalp, including trichoscopy features and pathomorphological markers. Topical therapy with glucocorticosteroids, keratolytics and agents with antifungal activity is of key importance in the treatment of papulosquamous diseases. Modern topical drugs with a fixed combination of active ingredients provide an effect on several pathogenetic mechanisms at once, are stable, compatible, and convenient for use by patients. One of the main drugs for the treatment of psoriasis and seborrheic dermatitis is a solution of betamethasone dipropionate and salicylic acid (trade name – Akriderm SK), which in terms of anti-inflammatory activity is comparable to the highest strength topical corticosteroids, while providing a faster response to therapy and effectively relieving symptoms of itching and peeling. This is confirmed by the authors’ own clinical experience and demonstrated in the clinical cases described in the article.
- Open Access
- 14 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 46-56
Comparative analysis of Health-Related Quality of Life, anxiety and depression in patients with alopecia areata, atopic dermatitis and with association of these diseases
Introduction. Alopecia areata (AA) and atopic dermatitis (AtD) are associated with significant psychosocial burden, emphasizing the importance of quality of life (QoL) assessment due to potential psychological distress and treatment hindrance.Aim. To conduct a comparative analysis of QoL, anxiety and depression in patients with AA, AtD and their combination, according to diseases severity.Materials and methods. The study included 91 patients of both sexes (18–52 years old). All patients were divided into 3 groups: group 1 – 25% patients with AA, group 2 – 28% with AtD, group 3 – 47% patients with both diseases; the groups were subdivided by dermatoses severity. The DLQI, Skindex-29 and HADS questionnaires were used. Mann-Whitney U-test was conducted to compare the mean values of quantitative data (М ± n) (p < 0.05).Results. Group 1 had moderately decreased QoL according to DLQI (6.5 ± 0.67); total Skindex-29 score was 23.55 ± 2.46 (low impact) with the highest value in the emotion domain. In group 2 DLQI score was 12.5 ± 1.51, total Skindex-29 score was48.41 ± 3.76; in group 3 DLQI was 11.5 ± 0.58, Skindex-29 – 50.46 ± 2.14. These values corresponded to very negative impact on QoL, increasing with diseases severity. There was a reliable difference in DLQI and Skindex-29 values between groups 1 and 2 and groups 1 and 3. Mean HADS scores in all groups were generally comparable and correlated with AtD and AA severity.Conclusion. Compared to AA, AtD has a greater impact on QoL, involving all areas of social health; AA predominantly affects emotional sphere. The presence of both diseases worsens QoL as well as AtD alone, especially in aspects “emotions” and “functions”.
- 14 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 46-56
Open AccessComparative analysis of Health-Related Quality of Life, anxiety and depression in patients with alopecia areata, atopic dermatitis and with association of these diseases
Introduction. Alopecia areata (AA) and atopic dermatitis (AtD) are associated with significant psychosocial burden, emphasizing the importance of quality of life (QoL) assessment due to potential psychological distress and treatment hindrance.Aim. To conduct a comparative analysis of QoL, anxiety and depression in patients with AA, AtD and their combination, according to diseases severity.Materials and methods. The study included 91 patients of both sexes (18–52 years old). All patients were divided into 3 groups: group 1 – 25% patients with AA, group 2 – 28% with AtD, group 3 – 47% patients with both diseases; the groups were subdivided by dermatoses severity. The DLQI, Skindex-29 and HADS questionnaires were used. Mann-Whitney U-test was conducted to compare the mean values of quantitative data (М ± n) (p < 0.05).Results. Group 1 had moderately decreased QoL according to DLQI (6.5 ± 0.67); total Skindex-29 score was 23.55 ± 2.46 (low impact) with the highest value in the emotion domain. In group 2 DLQI score was 12.5 ± 1.51, total Skindex-29 score was48.41 ± 3.76; in group 3 DLQI was 11.5 ± 0.58, Skindex-29 – 50.46 ± 2.14. These values corresponded to very negative impact on QoL, increasing with diseases severity. There was a reliable difference in DLQI and Skindex-29 values between groups 1 and 2 and groups 1 and 3. Mean HADS scores in all groups were generally comparable and correlated with AtD and AA severity.Conclusion. Compared to AA, AtD has a greater impact on QoL, involving all areas of social health; AA predominantly affects emotional sphere. The presence of both diseases worsens QoL as well as AtD alone, especially in aspects “emotions” and “functions”.